To identify genes controlling volatile anesthetic (VA) action, we have scre
ened through existing Caenorhabditis elegans mutants and found that strains
with a reduction in Go signaling are VA resistant. Loss-of-function mutant
s of the gene goa-l, which codes for the alpha -subunit of Go, have EC(50)s
for the VA isoflurane of 1.7- to 2.4-fold that of wild type. Strains overe
xpressing egl-10, which codes for an RGS protein negatively regulating goa-
l, are also isoflurane resistant. However, sensitivity to halothane, a stru
cturally distinct VA, is differentially affected by Go pathway mutants. The
RGS overexpressing strains, a goa-l missense mutant found to carry a novel
mutation near the GTP-binding domain, and eat-16(rf) mutants, which suppre
ss goa-1(gf) mutations, are all halothane resistant; gon-1(null) mutants ha
ve wild-type sensitivities. Double mutant strains carrying mutations in bot
h goa-l and unc-64, which codes for a neuronal syntaxin previously found to
regulate VA sensitivity, show that the syntaxin mutant phenotypes depend i
n part on goa-l expression. Pharmacological assays using the cholinesterase
inhibitor aldicarb suggest that VAs and GOA-1 similarly downregulate choli
nergic neurotransmitter release in C. elegans. Thus, the mechanism of actio
n of VAs in C. elegans is regulated by Goa, and presynaptic Go alpha -effec
tors are candidate VA molecular targets.